Ponte-Negretti CI, Isea-Pérez J, Lanas F, Medina J, Gómez-Mancebo J, Morales E, Acevedo M, Pirskorz D, Machado L, Lozada A, Bryce A, Lorenzatti A, Carrera C, López-Jaramillo P, Pinto X, Wyss-Quintana FS

Idioma: Ingles.
Referencias bibliográficas: 176
Paginas: 54-85
Archivo PDF: 469.64 Kb.

RESUMEN

La dislipidemia aterogénica (DA) es una entidad poco reconocida en las guías de práctica clínica actuales. Debido a las frecuentes alteraciones lipídicas asociadas a esta anomalía metabólica en América Latina (AL), hemos organizado un grupo de expertos que ha adoptado el nombre de Asociación Latinoamericana para el Estudio de Lípidos (ALALIP), para generar un documento en el que se analice la prevalencia en AL del perfil lipídico relacionado con esta afección y ofrecer recomendaciones prácticas para su óptimo diagnóstico y tratamiento. Metodología: Se seleccionó un grupo de expertos regionales y, utilizando una metodología Delphi modificada, se realizó una revisión bibliográfica exhaustiva, con énfasis en estudios o revisiones que tuvieran implicaciones para AL. Posteriormente se desarrolló una serie de preguntas clave sobre la epidemiología, la fisiopatología, el diagnóstico y el tratamiento de la DA, que fueron discutidas por el grupo de expertos. Como convención, las recomendaciones que tuvieron un 100% de aceptación fueron consideradas unánimes; aquellas con al menos el 80% como para el consenso, y de desacuerdo, aquellas con menos del 80%. Resultados: Aunque no existe un estudio global sobre los factores de riesgo que se haya realizado sobre la base de una muestra representativa de toda la población de AL, el análisis sistemático de las encuestas nacionales de salud y los estudios de cohortes regionales evidencian la alta prevalencia de las anormalidades lipídicas que definen la DA. La prevalencia de niveles bajos de colesterol de lipoproteínas de alta densidad (HDL-C) oscila entre el 34.1% (estudio CESCAS I) y el 53.3% (estudio LASO), con diferentes frecuencias entre hombres y mujeres y el punto de corte seleccionado. La prevalencia de triglicéridos elevados (TRG) varía de 25.5% (estudio LASO) a 31.2% (Encuesta Nacional de Salud de Chile) siendo siempre más prevalente en hombres que en mujeres. Sólo dos estudios informan la prevalencia de DA en AL: la Encuesta Nacional de Salud de México 2006 con un 18.3%, y un estudio venezolano que estima la prevalencia ponderada de la DA en 24.7%. Existen múltiples causas para estos hallazgos: una nutrición inadecuada –caracterizada por el alto consumo de alimentos con alta densidad calórica y un alto consumo de colesterol y grasas trans– un estilo de vida sedentario, una alta prevalencia de obesidad en la región y posiblemente cambios epigenéticos que hacen que nuestra población sea más susceptible a tener este perfil lipídico anormal. Conclusiones: Las anomalías lipídicas que definen la DA tienen una alta prevalencia en AL; la interacción entre el estilo de vida, la herencia, y los cambios epigenéticos posiblemente son su causa. Debido a que se consideran una causa importante de riesgo cardiovascular residual, deben ser diagnosticados y tratados activamente como un objetivo secundario después de alcanzar la meta para el colesterol de lipoproteína de baja densidad (LDL-C). Es importante diseñar un estudio global de los factores de riesgo en nuestra región para hacernos conocer la verdadera prevalencia de la DA y sus causas y ayudarnos en el diseño de políticas públicas adaptadas a nuestra realidad en una escala poblacional e individual.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Pedro-Botet J, Mantilla-Morató T, Díaz-Rodríguez A, Brea-Hernando A, González-Santos P, Hernández-Mijares A et al. El papel de la dislipemia aterogénica en las guías de práctica clínica. Clin Investig Arterioscler. 2016; 28 (2): 65-70.

2. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016; 118 (4): 547-563.

3. Ultra-processed food and drink products in Latin America: trends, impact on obesity, policy implications. Washington, DC: PAHO; 2015. ISBN 978-92-75-11864-1-9789275118641_en.

4. De Villiers M, De Villiers P, Athol K. The Delphi technique in health sciences education research. Med Teach. 2005; 27 (7): 639-643.

5. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990; 82 (2): 495-506.

6. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117 (6): 743-753.

7. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24 (11): 987-1003.

8. Lanas F, Serón P, Lanas A. Coronary heart disease and risk factors in Latin America. Glob Heart. 2013; 8 (4): 341-348.

9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 652 countries (The INTERHEART study): case control study. Lancet. 2004; 364: 937-952.

10. O’Donnell MJ, Xavier D, Lishung I, Zhang H, Chin SL et al. Risk factors for ischemic and hemorrhagic stroke in 22 countries: results of the first phase of INTERSTROKE in 6000 individuals. Lancet. 2010; 376: 112-123.

11. O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016; 388 (10046): 761-775.

12. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez-Pérez FJ, Rull JA et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation-wide survey. J Lipid Res. 2001; 42 (8): 1298-1307.

13. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Ávila M et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública; 2006. Available in: http: //epi.minsal.cl/estudios-y-encuestas-poblacionales/encuestas-poblacionales/encuesta-nacional-de-salud/resultados-ens/. Accessed February 15, 2015.

14. Encuesta Nacional de Chile. Available in: http: //epi.minsal.cl/estudios-y-encuestas-poblacionales/encuestas-poblacionales/encuesta-nacional-de-salud/resultados-ens/. Accessed February 15, 2015.

15. Pichardo R. Estudio de factores de riesgo cardiovascular en la República Dominicana (EFRICARD) 1996-1998. Archivos Dominicanos de Cardiología. 1998; 2: 3.

16. Miranda JJ, Herrera VM, Chirinos JA, Gómez LF, Perel P, Pichardo R et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One. 2013; 8 (1): e54056.

17. Rubinstein AL, Irazola VE, Calandrelli M, Elorriaga N, Gutierrez L et al. Multiple cardio metabolic risk factors in the Southern Cone of Latin America: a population-based study in Argentina, Chile, and Uruguay. Int J Cardiol. 2015; 183: 82-88.

18. Medina-Lezama J, Zea-Díaz H, Morey-Vargas OL, Bolaños-Salazar JF, Muñoz-Atahualpa E et al. Prevalence of the metabolic syndrome in Peruvian Andean hispanics: the PREVENCION study. Diabetes Res Clin Pract. 2007; 78 (2): 270-281.

19. Quispe R, Benziger CP, Bazo-Álvarez JC, Howe LD, Checkley W et al. CRONICAS cohort study group. The relationship between socioeconomic status and CV risk factors: the CRONICAS cohort study of peruvian adults. Glob Heart. 2016; 11 (1): 121-130.

20. Lazo-Porras M, Bernabe-Ortiz A, Málaga G, Gilman RH, Acuña-Villaorduña A, Cardenas-Montero D et al. Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study. Atherosclerosis. 2016; 246: 36-43.

21. Marcopito LF, Rodrigues SS, Pacheco MA, Shirassu MM, Goldfederer AJ, Moraes MA. Prevalence of a set of risk factors for chronic diseases in the city of São Paulo, Brazil. Rev Saude Publica. 2005; 39 (5): 738-745.

22. Garcez MR, Pereira JL, Fontanelli MM, Marchioni DM, Fisberg RM. Prevalence of dyslipidemia according to the nutritional status in a representative sample of São Paulo. Arq Bras Cardiol. 2014; 103 (6): 476-484.

23. Palomo I, Icaza G, Mujica V, Leiva E, Vásquez M, Alarcón M. Prevalencia de factores de riesgo cardiovascular clásicos en población adulta de Talca, Chile 2005. Rev Med Chile. 2007; 135: 904-912.

24. Meaney A, Ceballos-Reyes G, Gutiérrez-Salmean G, Samaniego-Méndez V, Vela-Huerta A et al. Cardiovascular risk factors in a Mexican middle-class urban population. The Linda vista study. Baseline data. Arch Cardiol Mex. 2013; 83 (4): 249-256.

25. García-Araujo M, Semprún-Fereira M, Sulbarán TA, Silva E, Calmón G, Campos G. Nutritional and metabolic factors as risk factors for cardiovascular diseases in an adult population in the city of Maracibo, Estado Zulia, Venezuela. Invest Clin. 2001; 42 (1): 23-42.

26. Nieto-Martínez R, Hamdy O, Marante D, Marulanda MI, Marchetti A, Hegazi RA et al. Transcultural diabetes nutrition algorithm (tDNA): Venezuelan application. Nutrients. 2014; 6 (4): 1333-1363.

27. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013; 62 (8): 697-703.

28. Gavrila D, Salmerón D, Egea-Caparrós JM, Huerta JM, Pérez-Martínez A, Navarro C et al. Prevalence of metabolic syndrome in Murcia Region, a southern European Mediterranean area with low cardiovascular risk and high obesity. BMC Public Health. 2011; 11: 562.

29. López-Jaramillo P, Pradilla LP, Castillo VR, Lahera V. Patología socio-económica como causa de las diferencias regionales en las prevalencias de síndrome metabólico e hipertensión inducida por el embarazo. Rev Esp Cardiol. 2007; 60 (2): 168-178.

30. López-Jaramillo P, Sánchez RA, Diaz M, Cobos L, Bryce A, Parra Carrillo JZ et al. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens. 2013; 31 (2): 223-238.

31. Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG et al. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys. BMJ. 2014; 348: g2272.

32. Monteiro CA, Moubarac JC, Cannon G, Ng SW, Popkin B. Ultra-processed products are becoming dominant in the global food system. Obes Rev. 2013; 14 Suppl 2: 21-28.

33. Moodie R, Stuckler D, Monteiro C, Sheron N, Neal B, Thamarangsi T et al. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet. 2013; 381 (9867): 670-679.

34. Euromonitor International. Blog.euromonitor.com, 2014, Accessed on March the v21st 2016.

35. Aguilar-Salinas C, Cañizales-Quinteros S, Rojas-Martínez R, Mehta R, Villarreal-Molina MT et al. Hypoalphalipoproteinemia in populations of native American ancestry: an opportunity to assess the interaction of genes and the environment. Curr Opin Lipidol. 2009; 20 (2): 92-97.

36. Khalil ChB. The emerging role of epigenetics in cardiovascular disease. Ther Adv Chronic Dis. 2014; 5 (4): 178-187.

37. López-Jaramillo P, Lahera V, López-López J. Epidemic of cardiometabolic diseases: a Latin American point of view. Ther Adv Cardiovasc Dis. 2011; 5 (2): 119-131.

38. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016; 12: 171-183.

39. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32: 1345-1361.

40. Arocha JI, Ponte-Negretti CI, Ablan F. Triglicéridos en ayunas y postprandiales: su contribución al estudio del riesgo cardiometabólico. Clin Invest Arterioscl. 2009; 21 (6): 290-297.

41. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003; 36 (6): 421-429.

42. Ponte-Negretti CI. Redescubriendo los triglicéridos como factor de riesgo cardiovascular. Avances Cardiol. 2009; 29 (4): 367-376.

43. Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009; 94 (3): 989-997.

44. Ponte-Negretti CI. Triglicérido: el padre de la dislipidemia mixta. En: Soltero I. Aterosclerosis al día VII. Asociación Venezolana de Aterosclerosis-AVA. Caracas: Ediciones Dulia 2021 C.A.; 2009.

45. Chan DC, Barrett HP, Watts GF. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs. 2004; 4 (4): 227-246.

46. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013; 93 (1): 359-404.

47. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006; 116 (9): 2464-2472.

48. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008; 7 (2): 95-96.

49. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125-1131.

50. Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of VLDL and LDL containing apolipoprotein C-III and no other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2010; 30 (2): 239.

51. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380 (9841): 581-590.

52. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298 (3): 309-316.

53. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298 (3): 299-308.

54. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK et al; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51 (7): 724-730.

55. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A. The emerging risk factors collaboration. major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000.

56. Varbo A, Benn M, Tybjaerg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a casual risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61 (4): 427-436.

57. Rosenson RS, Davidson MH, Hirsch BJ, Kathiresan S. Genetics and casuality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014; 64 (23): 2525-2540.

58. Stammler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? The multipe risk factor intervention trial. JAMA. 1996; 276: 882-888.

59. Fruchart JC, Packard CJ. Is cholesterol the major lipoprotein risk factor in coronary heart disease? A Franco-Scottish overview. Cur Med Res Opin. 1997; 13: 603.

60. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-1: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004; 255 (2): 188-205.

61. Orringer CE. Non-HDL cholesterol, Apo B and LDL particle concentration in coronary heart disease risk prediction and treatment. Clin Lipidol. 2013; 8 (1): 69-79.

62. Niggon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Research. 1991; 33: 1741-1753.

63. Björnheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall determined in an in vitro perfusion system. Atherosclerosis. 1996; 123 (1-2): 43-56.

64. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL sub-fraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996; 124: 261-271.

65. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein sub-fractions of differing density and particle size. Atherosclerosis. 1992; 93 (3): 189-199.

66. Younis NN, Soran H, Pemberton P, Charlton-Menys V, Elseweidy MM, Durrington PN. Small dense LDL is more susceptible to glycation than more buoyant LDL in type 2 diabetes. Clin Science. 2013; 124 (5): 343-349.

67. Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutrition Soc. 1999; 58: 163-169.

68. Lamarche B, St Pierre AC, Ruel IL, Cantin B, Dagenais GR, Després JP. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 2001; 17 (8): 859-865.

69. Kuller L, Arnold A, Tracy R, Otvos J, Burke G et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2002; 22: 1175-1180.

70. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Ratter S et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003; 107: 1733-1737.

71. Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR et al. Small dense low-density lipoprotein-Cholesterol concentrations predict risk for coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014; 34: 1069-1077.

72. Grammer TB, Kleber ME, März W, Silbernagel G, Siekmeier R et al. Low density lipoprotein particle and mortality: The Ludwigshafen risk and cardiovascular health study. Eur Heart J. 2015; 36: 31-38.

73. McPherson R. Remnant cholesterol “Non-(HDL-C + LDL-C)” as a coronary artery disease risk factor. J Am Coll Cardiol. 2013; 61 (4): 437-439.

74. Dallinga-Thie GM, Kroom J, Boren J, Chapman MJ. Triglyceride-rich lipoproteins and remnants: Tagets for therapy? Curr Cardiol Rep. 2016; 18 (67): 1-9.

75. Boren J, Taskinen MR, Olofsson SO, Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med. 2013; 274: 25-40.

76. Takahashi S, Sakai J, Fujimo T, Hattori H, Zenimaru Y et al. The very low-density lipoprotein (VLDL) receptor: characterization and function as a peripheral lipoprotein receptor. J Atheroscler Thromb. 2004; 11: 200-208.

77. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1994; 14: 1767-1774.

78. Proctor SD, Mamo JCL. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall: evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest. 1998; 28: 497-503.

79. Alanpovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Atheroscler Thromb Vasc Biol. 1997; 17: 715-722.

80. Goldberg IJ, Bornfeldt KE. Lipids and the endothelium: bidirectional interactions. Curr Atheroscler Rep. 2013; 15 (11): 365.

81. Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015; 36 (13): 774-776.

82. Riwanto M, Rohrer L, Roschitzki B, Beser C, Mocharla P et al. Altered activation of endothelial anti and proapoptotic pathways by high density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein proteome remodeling. Circulation. 2013; 127: 891-904.

83. Sacks FM, Zheng C, Cohn JS. Complexities of plasma apolipoprotein C-III metabolism. J Lipid Res. 2011; 52: 1067-1070.

84. Jensen MK, Rimm EB, Furtado JD, Sacks FM. Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. J Am Heart Assoc. 2012; 1 (2). pii: jah3-e000232.

85. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003; 107: 973-977.

86. Moyer MP, Tracy RP, Tracy PB, van’t Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol. 1998; 18: 458-465.

87. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Eng J Med. 2000; 342: 1792-1801.

88. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. Role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009; 50: S189-S194.

89. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006; 98 (1): 1352-1364.

90. Murphy AJ, Woolard KJ, Hoang A, Mukhamedova N, Stirzaker RA et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008; 28: 2071-2077.

91. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002; 13 (3): 285-288.

92. Park SH, Park JH, Kang JS, Kang YH. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol. 2003; 35: 168-182.

93. Sugano M, Tsuchida K, Makino N. High-density lipoprotein protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem Biophys Res Commun. 2000; 272: 872-876.

94. Calvo C. Bases moleculares de las propiedades antiaterogénicas de las lipoproteínas de alta densidad. Clin Invest Arterioscler. 2008; 20 (3): 116-125.

95. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper C et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290: 2292-2300.

96. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M et al. Cardiovascular status of carriers of the apolipoprotein A-1 (Milano) mutant: the Limone sul Garda study. Circulation. 2001; 103: 3047-3050.

97. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med. 1977; 62: 707-714.

98. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK et al. Major lipids, apolipoproteiins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000.

99. Gotto AM, Whitney E, Stein EA, Shapiro DF, Clearfield M et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Study (AFCAPS/TexCAPS). Circulation. 2000; 101: 477-484.

100. Barter PJ, Cauldfield M, Erickson M, Grundy SM, Kastelein JJ et al. Effects of Torcetrapib in patients at high risk for coronary events. N Eng J Med. 2007; 357: 2109-2122.

101. AIN HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BP, Desvignes-Nickens P et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365 (24): 2255-2267.

102. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T et al. HPS-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Eng J Med. 2014; 371: 203-212.

103. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ et al. On behalf of the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Eng J Med. 2012; 367: 2089-2099.

104. Niesor EJ, Schwartz GG, Perez A, Stauffer A, Durwell A et al. Statin-induced decrease in ATP-binding cassette transporter A1 expression via micro-RNA 33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther. 2015; 29: 7-14.

105. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet. 2012; 380: 572-580.

106. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation. 2012; 125: 1905-1919.

107. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur Heart J. 2015; 36: 22-30.

108. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroad of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev. 2006; 58: 342-374.

109. Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016; 13: 48-60.

110. López-Santi R. Enfoque terapéutico integral: abordaje no farmacológico. En: López-Santi R, Lorenzatti A, Priskorz D. Cardiometabolismo, de la fisiopatología a la terapéutica. 2014. pp: 237-248.

111. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D et al. PREDIMED study investigators. N Eng J Med. 2013; 368: 1279-1290.

112. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37 (29): 2315-2381.

113. Organización Panamericana de la Salud. Las Américas libres de grasas trans. Declaración de Río de Janeiro. Available in: http: //www.abia.org.br/anexos/02DeclaracionAGTRioESPANOLFINAL1.pdf.

114. Astrup A, Dyerberg J, Elwood P, Hermansen K, Hu FB, Jakobsen MU et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr. 2011; 93 (4): 684-688.

115. World Health Organization. Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition. WHO; 2008.

116. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010; 7 (3): e1000252.

117. Monteiro CA, Cannon G, Levy RB, Moubarac J-C, Jaime P et al. NOVA. The star shines bright [Food classification. Public health]. World Nutrition. 2016; 7 (1-3): 28-38.

118. Singh GM, Micha R, Khatibzadeh S, Lim S, Ezzati M, Mozaffarian D. Estimated global, regional and national burdens related to sugar-sweetened beverage consumption in 2010. Circulation. 2015; 132: 639-666.

119. Hu D, Huang J, Wang Y, Zhang D, Qu Y. Fruits and vegetables consumption and risk of stroke: a meta-analysis of prospective cohort studies. Stroke. 2014; 45 (6): 1613-1639.

120. Soltani S, Shirani F, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials. Obes Rev. 2016; 17 (5): 442-454.

121. Chiu S, Bergeron N, Williams PT, Bray GA, Sutherland B, Krauss RM. Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. Am J Clin Nutr. 2016; 103: 341-347.

122. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009; 301: 2024-2035.

123. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016; 37 (25): 1944-1958.

124. Friedewald VE, Jones PH, Mason P, Roberts R, Weintraub H. The editor’s round table: current perspectives on triglycerides and atherosclerosis. Am J Cardiol. 2016; 117 (10): 1697-1702.

125. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256 (20): 2823-2828.

126. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388 (10059): 2532-2561.

127. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37 (39): 2999-3058.

128. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129 (25 Suppl 2): S1-45.

129. Ponte C, Arocha J, Isea PJ, Gomez JR, Abblan F, Machado L et al. III Consenso venezolano para el manejo del paciente con dislipidemia. Avances Cardiológicos. 2014; 34 Supl 1.

130. Ben-Yehuda O, DeMaria AN. LDL-cholesterol targets after the ACC/AHA 2013 guidelines: evidence that lower is better? J Am Coll Cardiol. 2014; 64 (5): 495-497.

131. Boekholdt S, Hovingh G, Mora S, Arsenault B, Amarenco P, Pedersen T et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events a meta-analysis of statins trials. J Am Coll Cardiol. 2014; 64: 485-494.

132. Cannon C, Blazing M, Giugliano R, McCagg A, White J, Theroux P et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Eng J Med. 2015; 372: 2387-2397.

133. Brunzell J, Howard B, Davison, Stein J, Furberg C et al. Lipoprotein management in patients with cardio-metabolic risk. J Am Coll Cardiol. 2008; 51: 1512-1524.

134. Miller M, Hinsberg H, Schaefer E. Relative atherogenicity and predictive value of non high density lipoprotein cholesterol for coronary heart disease. Am J Cardiol. 2008; 101: 1003-1008.

135. Ballantyne CM, Bertolami M, Hernandez-Garcia H, Nul D, Stein E, Theroux P et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using Rosuvastatin therapy (MERCURY) II. J Am Coll Cardiol. 2008; 52: 626-632.

136. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004; 109 (23 Suppl 1): III2-III7.

137. Sniderman A, Williams K, Contois J, Monroe H, McQueen M, de Graaf J et al. A Meta-analysis of low -density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovacular risk. Circ Cardiovasc Qual Outcomes. 2011; 4: 337-345.

138. Carroll M, Kit B, Lacher D. Trends in elevated triglyceride in adults: United States, 2001-2012. NCHS Data Brief. 2015; (198): 198.

139. Miller M, Stone NJ, Ballantyne C, Bittner J, Criqui MH et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123 (20): 2292-2333.

140. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366 (9500): 1849-1861.

141. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317 (20): 1237-1245.

142. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000; 102 (1): 21-27.

143. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341 (6): 410-418.

144. Jun M, Foote C, Lv J, Neal B, Patel A et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375 (9729): 1875-1884.

145. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011; 217 (2): 492-498.

146. Lee MW, Park JK, Hong JW, Kim KJ, Shin DY, Ahn CW et al. Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy. Diabetes Metab J. 2013; 37 (3): 207-211.

147. Rauch B, Schiele R, Schneider S, Diller F, Victor N et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after a myocardial infarction. Circulation. 2010; 122 (21): 2152-2159.

148. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010; 363 (21): 2015-2026.

149. Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012; 5 (6): 808-818.

150. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999; 354 (9177): 447-455.

151. Yokoyama M, Origasa H, Matsuzaki M, Matsusawa Y, Saito Y et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369 (9567): 1090-1098.

152. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367 (4): 309-318.

153. Clinicaltrials.gov. [webpage on the Internet]. Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High CV Risk Patients with Hypertriglyceridemia (STRENGTH). 2015. Available from: https: //clinicaltrials.gov/ct2/show/NCT02104817. Accessed August 20, 2015.

154. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Issacsohn SL, Braeckman RA et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012; 110 (7): 984-992.

155. Harris WS, Ginsberg HN, Arunakul N, Shachteer NS, Windsor SL et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997; 4 (5-6): 385-391.

156. Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010; 10: 24.

157. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013; 34 (17): 1279-1291.

158. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013; 61 (4): 440-446.

159. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986; 8 (6): 1245-1255.

160. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010; 210 (2): 353-361.

161. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes). J Am Coll Cardiol. 2013; 62 (17): 1580-1584.

162. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007; 99 (6A): 22C-31C.

163. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005; 45 (2): 185-197.

164. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens. 2008; 22: 154-157.

165. Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. J Clin Lipidol. 2012; 6 (5): 413-426.

166. Driver SL, Martin SS, Gluckman TJ, Clary JM, Blumenthal RS, Stone NJ. Fasting or nonfasting lipid measurements: it depends on the question. J Am Coll Cardiol. 2016; 67 (10): 1227-1234.

167. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262.525 patients in 29 Western prospective studies. Circulation. 2007; 115: 450-458.

168. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA. 2012; 307 (12): 1302-1309.

169. Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC et al. Lipid-modifying therapies and risk of pancreatitis. A meta-analysis. JAMA. 2012; 308 (8): 804-811.

170. Batsis JA, Lopez-Jimenez F. Cardiovascular risk assessment: From individual risk prediction to estimation of global risk and change in risk in the population. BMJ Medicine. 2010; 108: 29. doi: 10.1186/1741-7015-8-29.

171. Grover S, Lowensteyn I. The challenges and benefits of cardiovascular risk assessment in clinical practice. Can J Cardiol. 2011; 27 (4): 481-487.

172. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286 (2): 180-187.

173. McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J. 2011; 32 (5): 581-589.

174. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2935-2959.

175. Evangelos CR, Evangelia EN. Association between Omega 3 fatty acid supplementation and risks of major cardiovascular disease events. JAMA. 2012; 308 (10): 1024-1103.

176. Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy? Curr Cardiol Rep. 2012; 14 (1): 112-124.